Targeting relevant signaling pathways—such as the neoplastic PI3K/Akt/mTOR pathway—revealed promising efficacy in monolayer NB cell cultures, and corresponding therapeutic agents were tested in various clinical trials [43]. This evidence concerns the gene AKT1 and neuroblastoma.